Growth hormone therapy of Turner's syndrome: beneficial effect on adult height.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (OX), in patients with Turner's syndrome (TS).

Who Took Part

According to the abstract, 70 girls were involved.

PubMed indexes the participants as young children and children, women only.

After completion of the first phase, group 3 subjects continued to receive GH only.

All other subjects were treated with GH plus OX.

How the Study Was Run

The design is described as randomized and multicenter.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

More than one site took part, so the girls came from several places.

Subjects were followed up until attainment of adult height and/or cessation of treatment.

Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens.

What Was Measured

PubMed files the paper under topics including Anabolic Agents, Body Height, Growth Hormone, Oxandrolone and Turner Syndrome.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 70 girls.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (The Journal of pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.